SciSparc Secures Strategic Advantage with Grant of European Patent
2024年5月31日 - 8:17PM
SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare diseases of the central
nervous system, announced today that the European Patent Office
granted the Company’s patent application titled “Compositions and
Methods of Potentiating Antimicrobials”. This is in addition to the
patent titled “Compositions and Methods of Potentiating
Antimicrobials” previously granted by the United States Patent and
Trademark Office. This patent grant bolsters the Company's
intellectual property portfolio, extending the protection of its
global patent holdings.
This grant not only reinforces SciSparc’s position in a key
market, but also enhances its competitive edge in the global
pharmaceutical landscape.
The patent describes the pharmaceutical compositions and methods
for potentiating various antimicrobials and minimizing their
side-effects. In particular, the invention relates to
pharmaceutical compositions comprising antibiotics and
cannabinoids, and optionally N-acylethanolamines, and use in
treating and/or preventing microbe biofilm formation and
microbe-induced pathologies. This innovation is important in the
context of antimicrobial and antibiotic resistance, a situation
that has led the World Health Organization to classify such
antimicrobial resistance as a serious threat.
SciSparc has been expanding its intellectual property portfolio,
with significant patents recently granted in Canada and Europe,
since the beginning of the year. This aggressive expansion
emphasizes SciSparc's commitment to securing its innovative
technologies globally and highlights the Company’s dynamic approach
to research and development. This addition marks another milestone
in SciSparc's ongoing efforts to safeguard its core technologies.
The Company's intellectual property portfolio now includes patents
across several major global territories, including the United
States, Europe, Japan, Australia, and Israel, comprising nine
patent families and two trademarks.
About SciSparc Ltd.
(Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. SciSparc’s focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive CBD: SCI-110 for the treatment of Tourette
Syndrome, for the treatment of Alzheimer's disease and agitation;
SCI-160 for the treatment of pain; and SCI- 210 for the treatment
of ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp
seeds oil-based products on the Amazon.com Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc uses forward-looking
statements when it discusses SciSparc’s competitive edge in the
market and the Company’s ongoing efforts to safeguard its core
technologies. Because such statements deal with future events and
are based on SciSparc's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, including
those discussed under the heading "Risk Factors" in SciSparc's
Annual Report on Form 20-F, as amended, filed with the SEC
on April 1, 2024, and in subsequent filings with the U.S.
Securities and Exchange Commission. Except as otherwise required by
law, SciSparc disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date they were made, whether as a result of new information, future
events or circumstances or otherwise.
Investor Contact: IR@scisparc.com Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
過去 株価チャート
から 8 2024 まで 9 2024
SciSparc (NASDAQ:SPRC)
過去 株価チャート
から 9 2023 まで 9 2024